DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATEdextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate capsule, extended release

Prasco Laboratories

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE extended release capsules (MAS-ER Capsules) safely and effectively. See full prescribing information for MAS-ER Capsules.

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE extended release capsules, for oral use, CII

Initial U.S. Approval: 2001

WARNING: ABUSE AND DEPENDENCE

See full prescribing information for complete boxed warning

- CNS stimulants, including MAS-ER Capsules, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence (5.1, 9.3)
- Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy (9.2, 9.3)
- ----- INDICATIONS AND USAGE

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE extended release capsules (MAS-ER Capsules), a CNS stimulant, are indicated for the treatment of attention deficit hyperactivity disorder (ADHD). (1)

- Children (ages 6-12): Efficacy was established in one 3-week outpatient, controlled trial and one analogue classroom, controlled trial in children with ADHD. (14)
- Adolescents (ages 13-17): Efficacy was established in one 4-week controlled trial in adolescents with • ADHD. (14)
- Adults: Efficacy was established in one 4-week controlled trial in adults with ADHD. (14)
- ------ DOSAGE AND ADMINISTRATION
- Pediatric patients (ages 6-17): 10 mg once daily in the morning. Maximum dose for children 6-12 years of age is 30 mg once daily. (2.2, 2.3, 2.4)
- Adults: 20 mg once daily in the morning. (2.5)
- Pediatric patients (ages 6-17) with severe renal impairment: 5 mg once daily in the morning. Maximum • dose for children 6-12 years of age with severe renal impairment is 20 mg once daily. (2.6, 8.6)
- Adults with severe renal impairment: 15 mg once daily in the morning. (2.6, 8.6) •
- Patients with ESRD: not recommended. (2.6, 8.6)

------ DOSAGE FORMS AND STRENGTHS -------

• Extended release capsules: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg (3)

------ CONTRAINDICATIONS

- Advanced arteriosclerosis (4)
- Symptomatic cardiovascular disease (4)
- Moderate to severe hypertension (4)
- Hyperthyroidism (4)
- Known hypersensitivity or idiosyncrasy to amphetamine (4)
- Glaucoma (4)
- Agitated states (4)

- History of drug abuse (4)
- During or within 14 days following the administration of monoamine oxidase inhibitors (MAOI) (4, 7.1)
- WARNINGS AND PRECAUTIONS
 Serious Cardiovascular Reactions: Sudden death has been reported with usual doses of CNS stimulants in children and adolescents with structural cardiac abnormalities or other serious heart problems; sudden death, stroke, and myocardial infarction have been reported in adults taking CNS stimulants at usual doses. Stimulant drugs should not be used in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems. (5.2)
- Increase in Blood Pressure: Monitor blood pressure and pulse at appropriate intervals. Use with caution in patients for whom blood pressure increases may be problematic. (5.2)
- Psychiatric Adverse Events: Stimulants may cause treatment-emergent psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychosis. Evaluate for bipolar disorder prior to stimulant use. Monitor for aggressive behavior. (5.3)
- Long-Term Suppression of Growth: Monitor height and weight at appropriate intervals. (5.4)
- Seizures: May lower the convulsive threshold. Discontinue in the presence of seizures. (5.5)
- Peripheral Vasculopathy, including Raynaud's phenomenon: Stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Careful observation for digital changes is necessary during treatment with ADHD stimulants. (5.6)
- Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. If it occurs, discontinue MAS-ER Capsules and initiate supportive treatment (4, 5.7, 10).
- Visual Disturbance: Difficulties with accommodation and blurring of vision have been reported with stimulant treatment. (5.8)
- Tics: May exacerbate tics. Evaluate for tics and Tourette's syndrome prior to stimulant administration. (5.9)

ADVERSE REACTIONS

- Children (ages 6 to 12): Most common adverse reactions (≥5% and with a higher incidence than on placebo) were loss of appetite, insomnia, abdominal pain, emotional lability, vomiting, nervousness, nausea, and fever. (6.1)
- Adolescents (ages 13 to 17): Most common adverse reactions (≥5% and with a higher incidence than on placebo) were loss of appetite, insomnia, abdominal pain, weight loss, and nervousness. (6.1)
- Adults: Most common adverse reactions ≥5% and with a higher incidence than on placebo were dry mouth, loss of appetite, insomnia, headache, weight loss, nausea, anxiety, agitation, dizziness, tachycardia, diarrhea, asthenia, and urinary tract infections. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-800-828-2088 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

- MAOI antidepressants are contraindicated; MAOIs potentiate the effects of amphetamine. Do not
- administer MAS-ER Capsules during or within 14 days after use of MAOI. (4, 7.1)
- Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (7.1)
- Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7.1)
- Adrenergic blockers, antihistamines, antihypertensives, phenobarbital, phenytoin, veratrum alkaloids, and ethosuximide: Effects may be reduced by amphetamines. (7.1)
- Tricyclic antidepressants, norepinephrine, and meperidine: Effects may be potentiated by amphetamines. (7.1)
 - USE IN SPECIFIC POPULATIONS
- Pregnancy: May cause fetal harm. (8.1)
- Lactation: Breastfeeding not recommended. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 2/2022

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ABUSE AND DEPENDENCE

1 INDICATIONS AND USAGE

1.1 Attention Deficit Hyperactivity Disorder

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Information Prior to Initiating Treatment
- 2.2 Dosing Considerations for All Patients
- 2.3 Children
- 2.4 Adolescents
- 2.5 Adults
- 2.6 Dosage in Patients with Renal Impairment

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Potential for Abuse and Dependence
- 5.2 Serious Cardiovascular Reactions
- 5.3 Psychiatric Adverse Events
- 5.4 Long-Term Suppression of Growth
- 5.5 Seizures
- 5.6 Peripheral Vasculopathy, including Raynaud's Phenomenon
- 5.7 Serotonin Syndrome
- 5.8 Visual Disturbance
- 5.9 Tics
- 5.10 Prescribing and Dispensing

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Adverse Reactions Associated with the Use of Amphetamine, MAS-ER Capsules, or ADDERALL

7 DRUG INTERACTIONS

7.1 Clinically Important Interactions with Amphetamines

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment

9 DRUG ABUSE AND DEPENDENCE

- 9.1 Controlled Substance
- 9.2 Abuse
- 9.3 Dependence

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including MAS-ER Capsules, other amphetaminecontaining products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy [see Warnings and Precautions (5.1) and Drug Abuse and Dependence (9.2, 9.3)].

1 INDICATIONS AND USAGE

1.1 Attention Deficit Hyperactivity Disorder

MAS-ER Capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

The efficacy of MAS-ER Capsules in the treatment of ADHD was established on the basis of two controlled trials in children aged 6 to 12, one controlled trial in adolescents aged 13 to 17, and one controlled trial in adults who met DSM-IV[®] criteria for ADHD [see Clinical Studies (14)].

A diagnosis of ADHD (DSM-IV[®]) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.

Special Diagnostic Considerations

Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of DSM-IV[®] characteristics.

Need for Comprehensive Treatment Program

MAS-ER Capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.

Long-Term Use

The effectiveness of MAS-ER Capsules for long-term use, i.e., for more than 3 weeks in children and 4 weeks in adolescents and adults, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use MAS-ER Capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

2 DOSAGE AND ADMINISTRATION

2.1 Important Information Prior to Initiating Treatment

Prior to initiating treatment with MAS-ER Capsules, assess for the presence of cardiac disease (e.g., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions (5.2)].

Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy. Maintain careful prescription records, educate patients about abuse, monitor for signs for abuse and overdose, and periodically re-evaluate the need for MAS-ER Capsules use [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9)].

2.2 Dosing Considerations for All Patients

Individualize the dosage according to the therapeutic needs and response of the patient. Administer MAS-ER Capsules at the lowest effective dosage.

Based on bioequivalence data, patients taking divided doses of immediate-release ADDERALL, (for example, twice daily), may be switched to MAS-ER Capsules at the same total daily dose taken once daily. Titrate at weekly intervals to appropriate efficacy and tolerability as indicated.

MAS-ER Capsules may be taken whole, or the capsule may be opened and the entire contents sprinkled on applesauce. If the patient is using the sprinkle administration method, the sprinkled applesauce should be consumed immediately; it should not be stored. Patients should take the applesauce with sprinkled beads in its entirety without chewing. The dose of a single capsule should not be divided. The contents of the entire capsule should be taken, and patients should not take anything less than one capsule per day.

MAS-ER Capsules may be taken with or without food.

MAS-ER Capsules should be given upon awakening. Afternoon doses should be avoided because of the potential for insomnia.

Where possible, MAS-ER Capsule therapy should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.

2.3 Children

In children with ADHD who are 6-12 years of age and are either starting treatment for the first time or switching from another medication, start with 10 mg once daily in the morning; daily dosage may be adjusted in increments of 5 mg or 10 mg at weekly intervals. When in the judgment of the clinician a lower initial dose is appropriate, patients may begin treatment with 5 mg once daily in the morning. The maximum recommended dose for children 6-12 years of age is 30 mg/day; doses greater than 30 mg/day have not been studied in children. MAS-ER Capsules have not been studied in children under 6 years of age.

2.4 Adolescents

The recommended starting dose for adolescents with ADHD who are 13-17 years of age and are either starting treatment for the first time or switching from another medication is 10 mg/day. The dose may be increased to 20 mg/day after one week if ADHD symptoms are not adequately controlled.

2.5 Adults

In adults with ADHD who are either starting treatment for the first time or switching from another medication, the recommended dose is 20 mg/day.

2.6 Dosage in Patients with Renal Impairment

In adult patients with severe renal impairment (GFR 15 to < 30 mL/min/1.73m²), the recommended dose is 15 mg once daily in the morning. In pediatric patients (6 to 17 years of age) with severe renal impairment, the recommended dose is 5 mg once daily. The maximum dose for children 6 to 12 years of age with severe renal impairment is 20 mg once daily. MAS-ER Capsules are not recommended in patients with end stage renal disease (ESRD) (GFR < 15 mL/min/1.73m²) [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

3 DOSAGE FORMS AND STRENGTHS

5 mg extended release capsules: Clear/blue (imprinted M. Amphet Salts 5 mg) 10 mg extended release capsules: Blue/blue (imprinted M. Amphet Salts 10 mg) 15 mg extended release capsules: Blue/white (imprinted M. Amphet Salts 15 mg) 20 mg extended release capsules: Orange/orange (imprinted M. Amphet Salts 20 mg) 25 mg extended release capsules: Orange/white (imprinted M. Amphet Salts 25 mg) 30 mg extended release capsules: Natural/orange (imprinted M. Amphet Salts 30 mg)

4 CONTRAINDICATIONS

MAS-ER Capsules administration is contraindicated in patients with the following conditions:

- Advanced arteriosclerosis
- Symptomatic cardiovascular disease
- Moderate to severe hypertension
- Hyperthyroidism
- In patients known to be hypersensitive to amphetamine, or other components of MAS-ER Capsules. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions (6.2)]
- Glaucoma
- Agitated states
- History of drug abuse
- Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.7) and Drug Interactions (7.1)]

5 WARNINGS AND PRECAUTIONS

5.1 Potential for Abuse and Dependence

CNS stimulants, including MAS-ER Capsules, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy [see Boxed Warning, Drug Abuse and Dependence (9.2, 9.3)].

5.2 Serious Cardiovascular Reactions

<u>Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart</u> <u>Problems</u>

Children and Adolescents

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug [see Contraindications (4)].

Adults

Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious

structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs [see Contraindications (4)].

Hypertension and Other Cardiovascular Conditions

Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia [see Contraindications (4) and Adverse Reactions (6)].

Assessing Cardiovascular Status in Patients being Treated with Stimulant Medications

Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g. electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.

5.3 Psychiatric Adverse Events

Pre-Existing Psychosis

Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorder.

Bipolar Illness

Particular care should be taken in using stimulants to treat ADHD patients with comorbid bipolar disorder because of concern for possible induction of mixed/manic episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

Emergence of New Psychotic or Manic Symptoms

Treatment-emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.

<u>Aggression</u>

Aggressive behavior or hostility is often observed in children and adolescents with

ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.

5.4 Long-Term Suppression of Growth

Monitor growth in children during treatment with stimulants. Patients who are not growing or gaining weight as expected may need to have their treatment interrupted.

Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and nonmedication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development.

In a controlled trial of MAS-ER Capsules in adolescents, mean weight change from baseline within the initial 4 weeks of therapy was -1.1 lbs. and -2.8 lbs., respectively, for patients receiving 10 mg and 20 mg MAS-ER Capsules. Higher doses were associated with greater weight loss within the initial 4 weeks of treatment. Chronic use of amphetamines can be expected to cause a similar suppression of growth.

5.5 Seizures

There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in the absence of seizures, and very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, MAS-ER Capsules should be discontinued.

5.6 Peripheral Vasculopathy, including Raynaud's Phenomenon

Stimulants, including MAS-ER Capsules, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.

5.7 Serotonin Syndrome

Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as MAOIs, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort *[see Drug Interactions (7.1)]*. Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism *[see Clinical Pharmacology (12.3)]*. The potential for a pharmacokinetic interaction exists with the co-administration of CYP2D6 inhibitors which may increase the risk with increased exposure to MAS-ER Capsules. In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 *[see Drug Interactions (7.1)]*. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

Concomitant use of MAS-ER Capsules with MAOI drugs is contraindicated [see Contraindications (4)].

Discontinue treatment with MAS-ER Capsules and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. Concomitant use of MAS-ER Capsules with other serotonergic drugs or CYP2D6 inhibitors should be used only if the potential benefit justifies the potential risk. If clinically warranted, consider initiating MAS-ER Capsules with lower doses, monitoring patients for the emergence of serotonin syndrome during drug initiation or titration, and informing patients of the increased risk for serotonin syndrome.

5.8 Visual Disturbance

Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.

5.9 Tics

Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome. Therefore, clinical evaluation for tics and Tourette's syndrome in patients and their families should precede use of stimulant medications.

5.10 Prescribing and Dispensing

The least amount of amphetamine feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. MAS-ER Capsules should be used with caution in patients who use other sympathomimetic drugs.

6 ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.1 Clinical Trials Experience

The premarketing development program for MAS-ER Capsules included exposures in a

total of 1315 participants in clinical trials (635 pediatric patients, 350 adolescent patients, 248 adult patients, and 82 healthy adult subjects). Of these, 635 patients (ages 6 to 12) were evaluated in two controlled clinical studies, one open-label clinical study, and two single-dose clinical pharmacology studies (N= 40). Safety data on all patients are included in the discussion that follows. Adverse reactions were assessed by collecting adverse reactions, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs.

Adverse reactions during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a smaller number of standardized event categories. In the tables and listings that follow, COSTART terminology has been used to classify reported adverse reactions.

The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed.

Adverse Reactions Leading to Discontinuation of Treatment

In two placebo-controlled studies of up to 5 weeks duration among children with ADHD, 2.4% (10/425) of MAS-ER Capsules-treated patients discontinued due to adverse reactions (including 3 patients with loss of appetite, one of whom also reported insomnia) compared to 2.7% (7/259) receiving placebo.

The most frequent adverse reactions leading to discontinuation of MAS-ER Capsules in controlled and uncontrolled, multiple-dose clinical trials of children (N=595) were anorexia (loss of appetite) (2.9%), insomnia (1.5%), weight loss (1.2%), emotional lability (1%), and depression (0.7%). Over half of these patients were exposed to MAS-ER Capsules for 12 months or more.

In a separate placebo-controlled 4-week study in adolescents with ADHD, five patients (2.1%) discontinued treatment due to adverse events among MAS-ER Capsules-treated patients (N=233) compared to none who received placebo (N=54). The most frequent adverse event leading to discontinuation and considered to be drug-related (i.e. leading to discontinuation in at least 1% of MAS-ER Capsules-treated patients and at a rate at least twice that of placebo) was insomnia (1.3%, n=3).

In one placebo-controlled 4-week study among adults with ADHD with doses 20 mg to 60 mg, 23 patients (12.0%) discontinued treatment due to adverse events among MAS-ER Capsules-treated patients (N=191) compared to one patient (1.6%) who received placebo (N=64). The most frequent adverse events leading to discontinuation and considered to be drug-related (i.e. leading to discontinuation in at least 1% of MAS-ER Capsules-treated patients and at a rate at least twice that of placebo) were insomnia (5.2%, n=10), anxiety (2.1%, n=4), nervousness (1.6%, n=3), dry mouth (1.6%, n=3), anorexia (1.6%, n=3), tachycardia (1.6%, n=3), headache (1.6%, n=3), and asthenia (1.0%, n=2).

Adverse Reactions Occurring in Controlled Trials

Adverse reactions reported in a 3-week clinical trial of children and a 4-week clinical trial in adolescents and adults, respectively, treated with MAS-ER Capsules or placebo are presented in the tables below.

Table 1 Adverse Reactions Reported by 2% or More of Children (6-12 Years Old) Receiving MAS-ER Capsules with Higher Incidence Than on Placebo in a 584-Patient Clinical Study

Body System	Preferred Term	MAS-ER Capsules (n=374)	Placebo (n=210)
	Abdominal Pain (stomachache)	14%	10%
Canaral	Fever	5%	2%
General	Infection	4%	2%
	Accidental Injury	3%	2%
	Asthenia (fatigue)	2%	0%
	Loss of Appetite	22%	2%
Digactiva System	Vomiting	7%	4%
Digestive System	Nausea	5%	3%
	Dyspepsia	2%	1%
	Insomnia	17%	2%
Norwour System	Emotional Lability	9%	2%
Nervous System	Nervousness	6%	2%
	Dizziness	2%	0%
Metabolic/Nutrition	al Weight Loss	4%	0%

Table 2 Adverse Reactions Reported by 5% or More of Adolescents (13-17 Years Old) Weighing ≤ 75 kg/165 lbs Receiving MAS-ER Capsules with Higher Incidence Than Placebo in a 287 Patient Clinical Forced Weekly-Dose Titration Study^{*}

Body System	Preferred Term	MAS-ER Capsules (n=233)	Placebo (n=54)
General	Abdominal Pain (stomachache)	11%	2%
Digestive System	Loss of Appetite [†]	36%	2%
Nervous System	Insomnia [†] Nervousness	12% 6%	4% 6% [‡]
Metabolic/Nutrition	al Weight Loss †	9%	0%

Note: The following reactions did not meet the criterion for inclusion in Table 2 but were reported by 2% to 4% of adolescent patients receiving MAS-ER Capsules with a higher incidence than patients receiving placebo in this study: accidental injury, asthenia (fatigue), dry mouth, dyspepsia, emotional lability, nausea, somnolence, and vomiting.

* Included doses up to 40 mg

† Dose-related adverse reactions

‡ Appears the same due to rounding

Table 3 Adverse Reactions Reported by 5% or More of Adults Receiving MAS-ER Capsules with Higher Incidence Than on Placebo in a 255 Patient Clinical Forced Weekly-Dose Titration Study^{*}

Body System	Preferred Term	MAS-ER Capsules (n=191)	Placebo (n=64)
General	Headache	26%	13%
General	Asthenia	6%	5%
	Dry Mouth	35%	5%
Digestive System	Loss of Appetite	33%	3%
Digestive System	Nausea	8%	3%
	Diarrhea	6%	0%
	Insomnia	27%	13%
	Agitation	8%	5%
Nervous System	Anxiety	8%	5%
	Dizziness	7%	0%
	Nervousness	13%	13% †
Cardiovascular System	Tachycardia	6%	3%
Metabolic/Nutritiona	Weight Loss	10%	0%
Urogenital System	Urinary Tract Infection	5%	0%

Note: The following reactions did not meet the criterion for inclusion in Table 3 but were reported by 2% to 4% of adult patients receiving MAS-ER Capsules with a higher incidence than patients receiving placebo in this study: infection, photosensitivity reaction, constipation, tooth disorder (e.g., teeth clenching, tooth infection), emotional lability, libido decreased, somnolence, speech disorder (e.g., stuttering, excessive speech), palpitation, twitching, dyspnea, sweating, dysmenorrhea, and impotence.

* Included doses up to 60 mg.

† Appears the same due to rounding

Hypertension [see Warnings and Precautions (5.2)]

In a controlled 4-week outpatient clinical study of adolescents with ADHD, isolated systolic blood pressure elevations \geq 15 mmHg were observed in 7/64 (11%) placebotreated patients and 7/100 (7%) patients receiving MAS-ER Capsules 10 or 20 mg. Isolated elevations in diastolic blood pressure \geq 8 mmHg were observed in 16/64 (25%) placebo-treated patients and 22/100 (22%) MAS-ER Capsules-treated patients. Similar results were observed at higher doses.

In a single-dose pharmacokinetic study in 23 adolescents with ADHD, isolated increases in systolic blood pressure (above the upper 95% CI for age, gender, and stature) were observed in 2/17 (12%) and 8/23 (35%), subjects administered 10 mg and 20 mg MAS-ER Capsules, respectively. Higher single doses were associated with a greater increase in systolic blood pressure. All increases were transient, appeared maximal at 2 to 4 hours post dose and not associated with symptoms.

6.2 Adverse Reactions Associated with the Use of Amphetamine, MAS-ER Capsules, or ADDERALL

The following adverse reactions have been identified during post-approval use of amphetamine, MAS-ER Capsules, or ADDERALL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

<u>Cardiovascular</u>

Palpitations. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.

Central Nervous System

Psychotic episodes at recommended doses, overstimulation, restlessness, irritability, euphoria, dyskinesia, dysphoria, depression, tremor, tics, aggression, anger, logorrhea, dermatillomania, paresthesia (including formication), and bruxism.

Eye Disorders

Vision blurred, mydriasis.

Gastrointestinal

Unpleasant taste, constipation, intestinal ischemia, and other gastrointestinal disturbances.

<u>Allergic</u>

Urticaria, rash, hypersensitivity reactions including angioedema and anaphylaxis. Serious skin rashes, including Stevens-Johnson Syndrome and toxic epidermal necrolysis have been reported.

Endocrine

Impotence, changes in libido, frequent or prolonged erections.

<u>Skin</u>

Alopecia.

Vascular Disorders

Raynaud's phenomenon.

Musculoskeletal and Connective Tissue Disorders

Rhabdomyolysis

7 DRUG INTERACTIONS

7.1 Clinically Important Interactions with Amphetamines

Table 4: Drugs Having Clinically Important Interactionswith Amphetamines

Monoamine Oxidase Inhibitors (MAOIs)

Clinical Impact	Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.
Intervention	Do not administer MAS-ER Capsules concomitantly or within 14 days after discontinuing MAOI [see Contraindications (4)].
Examples	selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue
Serotonerg	ic Drugs
Clinical Impact	The concomitant use of MAS-ER Capsules and serotonergic drugs increases the risk of serotonin syndrome.
Intervention	Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during MAS-ER Capsules initiation or dosage increase. If serotonin syndrome occurs, discontinue MAS-ER Capsules and the concomitant serotonergic drug(s) [see Warnings and Precautions (5.7)].
Examples	selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort
CYP2D6 Inl	nibitors
Clinical Impact	The concomitant use of MAS-ER Capsules and CYP2D6 inhibitors may increase the exposure of MAS-ER Capsules compared to the use of the drug alone and increase the risk of serotonin syndrome.
Intervention	Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during MAS-ER Capsules initiation and after a dosage increase. If serotonin syndrome occurs, discontinue MAS-ER Capsules and the CYP2D6 inhibitor [see Warnings and Precautions (5.7) and Overdosage (10)].
Examples	paroxetine and fluoxetine (also serotonergic drugs), quinidine, ritonavir
Alkalinizing	Agents
Clinical Impact	Increase blood levels and potentiate the action of amphetamine.
Intervention	Co-administration of MAS-ER Capsules and gastrointestinal or urinary alkalinizing agents should be avoided.
Examples	Gastrointestinal alkalinizing agents (e.g., sodium bicarbonate). Urinary alkalinizing agents (e.g.

	acetazolamide, some thiazides).
Acidifying A	gents
Clinical Impact	Lower blood levels and efficacy of amphetamines.
Intervention	Increase dose based on clinical response.
Examples	Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid). Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts).
Tricyclic An	tidepressants
Clinical Impact	May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d- amphetamine in the brain; cardiovascular effects can be potentiated.
Intervention	Monitor frequently and adjust or use alternative therapy based on clinical response.
Examples	desipramine, protriptyline
Proton Pun	np Inhibitors
Clinical Impact	Time to maximum concentration (T _{max}) of amphetamine is decreased compared to when administered alone.
Intervention	Monitor patients for changes in clinical effect and adjust therapy based on clinical response.
Examples	Omeprazole

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to MAS-ER Capsules during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/othermedications/.

<u>Risk Summary</u>

Available data from published epidemiologic studies and postmarketing reports on use of prescription amphetamine in pregnant women have not identified a drug-associated risk of major birth defects and miscarriage (*see Data*). Adverse pregnancy outcomes, including premature delivery and low birth weight, have been seen in infants born to mothers taking amphetamines during pregnancy (*see Clinical Considerations*).

No apparent effects on morphological development were observed in embryo-fetal development studies, with oral administration of amphetamine to rats and rabbits during organogenesis at doses 2 and 12 times, respectively, the maximum recommended human dose (MRHD) of 20 mg/day given to adolescents, on a mg/m² basis. However, in

a pre- and post-natal development study, amphetamine (*d*- to *l*- ratio of 3:1) administered orally to pregnant rats during gestation and lactation caused a decrease in pup survival and a decrease in pup body weight that correlated with a delay in developmental landmarks at clinically relevant doses of amphetamine. In addition, adverse effects on reproductive performance were observed in pups whose mothers were treated with amphetamine. Long-term neurochemical and behavioral effects have also been reported in animal developmental studies using clinically relevant doses of amphetamine (*see Data*).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Amphetamines, such as MAS-ER Capsules, cause vasoconstriction and thereby may decrease placental perfusion. In addition, amphetamines can stimulate uterine contractions, increasing the risk of premature delivery. Infants born to mothers taking amphetamines during pregnancy have an increased risk of premature delivery and low birth weight.

Monitor infants born to mothers taking amphetamines for symptoms of withdrawal such as feeding difficulties, irritability, agitation, and excessive drowsiness.

<u>Data</u>

Animal Data

Amphetamine (*d*- to *l*- enantiomer ratio of 3:1) had no apparent effects on embryofetal morphological development or survival when administered orally to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately 2 and 12 times, respectively, the maximum recommended human dose (MRHD) of 20 mg/day given to adolescents, on a mg/m² basis. Fetal malformations and death have been reported in mice following parenteral administration of *d*-amphetamine doses of 50 mg/kg/day (approximately 10 times the MRHD given to adolescents on a mg/m² basis) or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity.

A study was conducted in which pregnant rats received daily oral doses of amphetamine (*d*- to *l*- enantiomer ratio of 3:1) of 2, 6, and 10 mg/kg from gestation day 6 to lactation day 20. These doses are approximately 0.8, 2, and 4 times the MRHD of 20 mg/day given to adolescents, on a mg/m² basis. All doses caused hyperactivity and decreased weight gain in the dams. A decrease in pup survival was seen at all doses. A decrease in pup body weight was seen at 6 and 10 mg/kg which correlated with delays in developmental landmarks, such as preputial separation and vaginal opening. Increased pup locomotor activity was seen at 10 mg/kg on day 22 postpartum but not at 5 weeks postweaning. When pups were tested for reproductive performance at maturation, gestational weight gain, number of implantations, and number of delivered pups were decreased in the group whose mothers had been given 10 mg/kg.

A number of studies from the literature in rodents indicate that prenatal or early

postnatal exposure to amphetamine (d- or d, l-) at doses similar to those used clinically can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function.

8.2 Lactation

<u>Risk Summary</u>

Based on limited case reports in published literature, amphetamine (*d*- or *d*, *l*-) is present in human milk, at relative infant doses of 2% to 13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9 and 7.5. There are no reports of adverse effects on the breastfed infant. Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is possible that large dosages of amphetamine might interfere with milk production, especially in women whose lactation is not well established. Because of the potential for serious adverse reactions in nursing infants, advise patients that breastfeeding is not recommended during treatment with MAS-ER Capsules.

8.4 Pediatric Use

MAS-ER Capsules are indicated for use in children 6 years of age and older.

The safety and efficacy of MAS-ER Capsules in children under 6 years of age have not been studied. Long-term effects of amphetamines in children have not been well established.

Long-Term Growth Suppression

Growth should be monitored during treatment with stimulants, including MAS-ER Capsules, and pediatric patients aged 6 to 17 years who are not growing or gaining weight as expected may need to have their treatment interrupted [see Warnings and Precautions (5.4)].

Juvenile Animal Toxicity Data

Juvenile rats treated with mixed amphetamine salts early in the postnatal period through sexual maturation demonstrated transient changes in motor activity. Learning and memory was impaired at approximately 6 times the maximum recommended human dose (MRHD) given to children on a mg/m² basis. No recovery was seen following a drug free period. A delay in sexual maturation was observed at a dose approximately 6 times the MRHD given to children on a mg/m² basis, although there was no effect on fertility.

In a juvenile developmental study, rats received daily oral doses of amphetamine (*d* to *l* enantiomer ratio of 3:1) of 2, 6, or 20 mg/kg on days 7-13 of age; from day 14 to approximately day 60 of age these doses were given b.i.d. for total daily doses of 4, 12, or 40 mg/kg. The latter doses are approximately 0.6, 2, and 6 times the MRHD of 30 mg/day, given to children on a mg/m² basis. Post dosing hyperactivity was seen at all doses; motor activity measured prior to the daily dose was decreased during the dosing period but the decreased motor activity was largely absent after an 18 day drug-free recovery period. Performance in the Morris water maze test for learning and memory was impaired at the 40 mg/kg dose, and sporadically at the lower doses, when measured prior to the daily dose during the treatment period; no recovery was seen after a 19 day drug-free period. A delay in the developmental milestones of vaginal

opening and preputial separation was seen at 40 mg/kg but there was no effect on fertility.

8.5 Geriatric Use

MAS-ER Capsules have not been studied in the geriatric population.

8.6 Renal Impairment

Due to reduced clearance of amphetamines in patients with severe renal impairment (GFR 15 to <30 mL/min/1.73m²), the recommended dose should be reduced. MAS-ER Capsules are not recommended in patients with ESRD (GFR < 15 ml/min/1.73m²) [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)].

d-Amphetamine is not dialyzable.

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

MAS-ER Capsules contain amphetamine, a Schedule II controlled substance.

9.2 Abuse

MAS-ER Capsules are CNS stimulants that contain amphetamine, which has a high potential for abuse. Abuse is characterized by impaired control of drug use, compulsive use despite harm, and craving.

Signs and symptoms of amphetamine abuse may include increased heart rate, respiratory rate, blood pressure, and/or sweating, dilated pupils, hyperactivity, restlessness, insomnia, decreased appetite, loss of coordination, tremors, flushed skin, vomiting, and/or abdominal pain. Anxiety, psychosis, hostility, aggression, suicidal or homicidal ideation have also been observed. Abusers of amphetamines may use other unapproved routes of administration which can result in overdose and death [see Overdosage (10)].

To reduce the abuse of CNS stimulants, including MAS-ER Capsules, assess the risk of abuse prior to prescribing. After prescribing, keep careful prescription records, educate patients and their families about abuse and proper storage and disposal of CNS stimulants. Monitor for signs of abuse while on therapy and re-evaluate the need for MAS-ER Capsules use.

9.3 Dependence

Tolerance (a state of adaptation in which exposure to a specific dose of a drug results in a reduction of the drug's desired and/or undesired effects over time, in such a way that a higher dose of the drug is required to produce the same effect that was once obtained at a lower dose) may occur during chronic therapy of CNS stimulants including MAS-ER Capsules.

Physical Dependence (which is manifested by a withdrawal syndrome produced by abrupt cessation, rapid dose reduction, or administration of an antagonist) may occur in patients treated with CNS stimulants including MAS-ER Capsules. Withdrawal symptoms

after abrupt cessation of CNS stimulants include dysphoric mood; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.

10 OVERDOSAGE

Manifestations of amphetamine overdose include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Serotonin syndrome has been reported with amphetamine use, including MAS-ER Capsules. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.

<u>Treatment</u>

Consult with a Certified Poison Control Center for up to date guidance and advice.

The prolonged release of mixed amphetamine salts from MAS-ER Capsules should be considered when treating patients with overdose.

d-Amphetamine is not dialyzable.

11 DESCRIPTION

MAS-ER Capsules contain mixed salts of a single-entity amphetamine, a CNS stimulant. MAS-ER Capsules contain equal amounts (by weight) of four salts: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate and amphetamine (D,L)aspartate monohydrate. This results in a 3.1:1 mixture of dextro- to levo- amphetamine base equivalent.

The 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg strength extended release capsules are for oral administration. MAS-ER Capsules contain two types of drug-containing beads (immediate-release and delayed release) which prolong the release of amphetamine compared to the ADDERALL (immediate-release) tablet formulation.

Each capsule contains:

Capsule Strength	5 mg	10 mg	15 mg	20 mg	25 mg	30 mg
Dextroamphetamine	1.25	2.5	3.75	5.0	6.25	7.5
Saccharate	mg	mg	mg	mg	mg	mg
Amphetamine (D,L)-	1.25	2.5	3.75	5.0	6.25	7.5
Aspartate Monohydrate	mg	mg	mg	mg	mg	mg
Dextroamphetamine	1.25	2.5	3.75	5.0	6.25	7.5
Sulfate	mg	mg	mg	mg	mg	mg
Amphetamine Sulfate	1.25	2.5	3.75	5.0	6.25	7.5
Amphetamile Sullate	mg	mg	mg	mg	mg	mg
Total amphetamine base	3.1	6.3	9.4	12.5	15.6	18.8
equivalence	mg	mg	mg	mg	mg	mg

d-amphetamine base	2.4	4.7	7.1	9.5	11.9	14.2
equivalence	mg	mg	mg	mg	mg	mg
<i>I</i> -amphetamine base	0.75	1.5	2.3	3.0	3.8	4.5
equivalence	mg	mg	mg	mg	mg	mg

Inactive Ingredients and Colors

The inactive ingredients in MAS-ER Capsules include: gelatin capsules, hydroxypropyl methylcellulose, methacrylic acid copolymer, opadry beige, sugar spheres, talc, and triethyl citrate. Gelatin capsules contain edible inks, kosher gelatin, and titanium dioxide. The 5 mg, 10 mg, and 15 mg capsules also contain FD&C Blue #2. The 20 mg, 25 mg, and 30 mg capsules also contain red iron oxide and yellow iron oxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.

12.2 Pharmacodynamics

Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

12.3 Pharmacokinetics

Pharmacokinetic studies of MAS-ER Capsules have been conducted in healthy adult and pediatric (children aged 6-12 yrs) subjects, and adolescent (13-17 yrs) and children with ADHD. Both ADDERALL (immediate-release) tablets and MAS-ER extended release capsules contain d-amphetamine and l-amphetamine salts in the ratio of 3:1. Following administration of ADDERALL (immediate-release), the peak plasma concentrations occurred in about 3 hours for both d-amphetamine and l-amphetamine and l-amphetamine.

The time to reach maximum plasma concentration (T_{max}) for MAS-ER Capsules is about 7 hours, which is about 4 hours longer compared to ADDERALL (immediate-release). This is consistent with the extended-release nature of the product.




Figure 1 Mean d-amphetamine and l-amphetamine Plasma Concentrations Following Administration of MAS-ER Capsules 20 mg (8 am) and ADDERALL (immediate-release) 10 mg Twice Daily (8 am and 12 noon) in the Fed State.

A single dose of MAS-ER 20 mg capsules provided comparable plasma concentration profiles of both d-amphetamine and l-amphetamine to ADDERALL (immediate-release) 10 mg twice daily administered 4 hours apart.

The mean elimination half-life for d-amphetamine is 10 hours in adults; 11 hours in adolescents aged 13-17 years and weighing less than or equal to 75 kg/165 lbs; and 9 hours in children aged 6 to 12 years. For the l-amphetamine, the mean elimination half-life in adults is 13 hours; 13 to 14 hours in adolescents; and 11 hours in children aged 6 to 12 years. On a mg/kg body weight basis, children have a higher clearance than adolescents or adults (see Special Populations below).

MAS-ER Capsules demonstrates linear pharmacokinetics over the dose range of 20 to 60 mg in adults and adolescents weighing greater than 75 kg/165 lbs, over the dose range of 10 to 40 mg in adolescents weighing less than or equal to 75 kg/165 lbs, and 5 to 30 mg in children aged 6 to 12 years. There is no unexpected accumulation at steady state in children.

Food does not affect the extent of absorption of d-amphetamine and l-amphetamine, but prolongs T_{max} by 2.5 hours (from 5.2 hrs at fasted state to 7.7 hrs after a high-fat meal) for d-amphetamine and 2.7 hours (from 5.6 hrs at fasted state to 8.3 hrs after a high fat meal) for l-amphetamine after administration of MAS-ER Capsules 30 mg. Opening the capsule and sprinkling the contents on applesauce results in comparable absorption to the intact capsule taken in the fasted state. Equal doses of MAS-ER Capsules strengths are bioequivalent.

Metabolism and Excretion

Amphetamine is reported to be oxidized at the 4 position of the benzene ring to form 4hydroxyamphetamine, or on the side chain α or β carbons to form alpha-hydroxyamphetamine or norephedrine, respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is subsequently oxidized to form 4-hydroxy-norephedrine. Alpha-hydroxy-amphetamine undergoes deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility.

Amphetamine is known to inhibit monoamine oxidase, whereas the ability of amphetamine and its metabolites to inhibit various P450 isozymes and other enzymes has not been adequately elucidated. *In vitro* experiments with human microsomes indicate minor inhibition of CYP2D6 by amphetamine and minor inhibition of CYP1A2, 2D6, and 3A4 by one or more metabolites. However, due to the probability of autoinhibition and the lack of information on the concentration of these metabolites relative to *in vivo* concentrations, no predications regarding the potential for amphetamine or its metabolites to inhibit the metabolism of other drugs by CYP isozymes *in vivo* can be made.

With normal urine pHs, approximately half of an administered dose of amphetamine is recoverable in urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30-40% of the dose is recoverable in urine as amphetamine itself. Since amphetamine has a pKa of 9.9, urinary recovery of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal elimination with clearances greater than glomerular filtration rates, indicating the involvement of active secretion. Urinary recovery of amphetamine has been reported to range from 1% to 75%, depending on urinary pH, with the remaining fraction of the dose hepatically metabolized. Consequently, both hepatic and renal dysfunction have the potential to inhibit the elimination of amphetamine and result in prolonged exposures. In addition, drugs that effect urinary pH are known to alter the elimination of amphetamine, and any decrease in amphetamine's metabolism that might occur due to drug interactions or genetic polymorphisms is more likely to be clinically significant when renal elimination is decreased [see Drug Interactions (7)].

Special Populations

Comparison of the pharmacokinetics of d- and l-amphetamine after oral administration of MAS-ER Capsules in children (6-12 years) and adolescent (13-17 years) ADHD patients and healthy adult volunteers indicates that body weight is the primary determinant of apparent differences in the pharmacokinetics of d- and l-amphetamine across the age range. Systemic exposure measured by area under the curve to infinity (AUC_∞) and maximum plasma concentration (C_{max}) decreased with increases in body weight, while oral volume of distribution (V_Z/F), oral clearance (CL/F), and elimination half-life ($t_{1/2}$) increased with increases in body weight.

Pediatric Patients

On a mg/kg weight basis, children eliminated amphetamine faster than adults. The elimination half-life ($t_{1/2}$) is approximately 1 hour shorter for d-amphetamine and 2 hours shorter for l-amphetamine in children than in adults. However, children had higher systemic exposure to amphetamine (C_{max} and AUC) than adults for a given dose of MAS-ER Capsules, which was attributed to the higher dose administered to children on a mg/kg body weight basis compared to adults. Upon dose normalization on a mg/kg basis, children showed 30% less systemic exposure compared to adults.

Gender

Systemic exposure to amphetamine was 20-30% higher in women (N=20) than in men (N=20) due to the higher dose administered to women on a mg/kg body weight basis. When the exposure parameters (C_{max} and AUC) were normalized by dose (mg/kg), these differences diminished. Age and gender had no direct effect on the pharmacokinetics of d- and l-amphetamine.

Race

Formal pharmacokinetic studies for race have not been conducted. However, amphetamine pharmacokinetics appeared to be comparable among Caucasians (N=33), Blacks (N=8) and Hispanics (N=10).

Patients with Renal Impairment

The effect of renal impairment on *d*- and *l*-amphetamine after administration of MAS-ER Capsules has not been studied. The impact of renal impairment on the disposition of amphetamine is expected to be similar between oral administration of lisdexamfetamine and MAS-ER Capsules.

In a pharmacokinetic study of lisdexamfetamine in adult subjects with normal and impaired renal function, mean d-amphetamine clearance was reduced from 0.7 L/hr/kg in normal subjects to 0.4 L/hr/kg in subjects with severe renal impairment (GFR 15 to <30mL/min/1.73m²). Dialysis did not significantly affect the clearance of *d*-amphetamine [see Use in Specific Populations (8.6)].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

<u>Carcinogenesis</u>

No evidence of carcinogenicity was found in studies in which *d*,*l*-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day given to children, on a mg/m² basis.

<u>Mutagenesis</u>

Amphetamine, in the enantiomer ratio d- to l- ratio of 3:1, was not clastogenic in the mouse bone marrow micronucleus test *in vivo* and was negative when tested in the *E. coli* component of the Ames test *in vitro*. *d*,*l*-Amphetamine (1:1 enantiomer ratio) has

been reported to produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the *in vitro* sister chromatid exchange and chromosomal aberration assays.

Impairment of Fertility

Amphetamine, in the enantiomer ratio d- to l- ratio of 3:1, did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 8 times the maximum recommended human dose of 20 mg/day given to adolescents, on a mg/m² basis).

13.2 Animal Toxicology and/or Pharmacology

Acute administration of high doses of amphetamine (d- or d,l-) has been shown to produce long-lasting neurotoxic effects, including irreversible nerve fiber damage, in rodents. The significance of these findings to humans is unknown.

14 CLINICAL STUDIES

Pediatric Patients

A double-blind, randomized, placebo-controlled, parallel-group study was conducted in children aged 6-12 (N=584) who met DSM-IV[®] criteria for ADHD (either the combined type or the hyperactive-impulsive type). Patients were randomized to fixed-dose treatment groups receiving final doses of 10, 20, or 30 mg of MAS-ER Capsules or placebo once daily in the morning for three weeks. Significant improvements in patient behavior, based upon teacher ratings of attention and hyperactivity, were observed for all MAS-ER Capsules doses compared to patients who received placebo, for all three weeks, including the first week of treatment, when all MAS-ER Capsules subjects were receiving a dose of 10 mg/day. Patients who received MAS-ER Capsules showed behavioral improvements in both morning and afternoon assessments compared to patients on placebo.

In a classroom analogue study, patients (N=51) receiving fixed doses of 10 mg, 20 mg or 30 mg MAS-ER Capsules demonstrated statistically significant improvements in teacher-rated behavior and performance measures, compared to patients treated with placebo.

A double-blind, randomized, multi-center, parallel-group, placebo-controlled study was conducted in adolescents aged 13-17 (N=327) who met DSM-IV[®] criteria for ADHD. The primary cohort of patients (n=287, weighing \leq 75kg/165lbs) was randomized to fixeddose treatment groups and received four weeks of treatment. Patients were randomized to receive final doses of 10 mg, 20 mg, 30 mg, and 40 mg MAS-ER Capsules or placebo once daily in the morning. Patients randomized to doses greater than 10 mg were titrated to their final doses by 10 mg each week. The secondary cohort consisted of 40 subjects weighing >75kg/165lbs who were randomized to fixed-dose treatment groups receiving final doses of 50 mg and 60 mg MAS-ER Capsules or placebo once daily in the morning for 4 weeks. The primary efficacy variable was the Attention Deficit Hyperactivity Disorder-Rating Scale IV (ADHD-RS-IV) total score for the primary cohort. The ADHD-RS-IV is an 18-item scale that measures the core symptoms of ADHD. Improvements in the primary cohort were statistically significantly greater in all four primary cohort active treatment groups (MAS-ER Capsules 10 mg, 20 mg, 30 mg, and 40 mg) compared with the placebo group. There was not adequate evidence that doses greater than 20 mg/day conferred additional benefit.

Adult Patients

A double-blind, randomized, placebo-controlled, parallel-group study was conducted in adults (N=255) who met DSM-IV[®] criteria for ADHD. Patients were randomized to fixeddose treatment groups receiving final doses of 20, 40, or 60 mg of MAS-ER Capsules or placebo once daily in the morning for four weeks. Significant improvements, measured with the Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS), an 18- item scale that measures the core symptoms of ADHD, were observed at endpoint for all MAS-ER Capsules doses compared to patients who received placebo for all four weeks. There was not adequate evidence that doses greater than 20 mg/day conferred additional benefit.

16 HOW SUPPLIED/STORAGE AND HANDLING

5 mg extended release capsules: Clear/blue (imprinted M. Amphet Salts 5 mg), bottles of 100, NDC 66993-594-02

10 mg extended release capsules: Blue/blue (imprinted M. Amphet Salts 10 mg), bottles of 100, NDC 66993-595-02

15 mg extended release capsules: Blue/white (imprinted M. Amphet Salts 15 mg), bottles of 100, NDC 66993-596-02

20 mg extended release capsules: Orange/orange (imprinted M. Amphet Salts 20 mg), bottles of 100, NDC 66993-597-02

25 mg extended release capsules: Orange/white (imprinted M. Amphet Salts 25 mg), bottles of 100, NDC 66993-598-02

30 mg extended release capsules: Natural/orange (imprinted M. Amphet Salts 30 mg), bottles of 100, NDC 66993-599-02

Dispense in a tight, light-resistant container as defined in the USP.

Store at room temperature, 20° C to 25° C (68° F to 77° F). Excursions permitted to 15-30° C (59-86º F) [see USP Controlled Room Temperature].

<u>Disposal</u>

Comply with local laws and regulations on drug disposal of CNS stimulants. Dispose of remaining, unused, or expired MAS-ER Capsules at authorized collection sites such as retail pharmacies, hospital or clinic pharmacies, and law enforcement locations. If no take-back program or authorized collector is available, mix MAS-ER Capsules with an undesirable, nontoxic substance to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and discard MAS-ER Capsules in the household trash.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Controlled Substance Status/Potential for Abuse, Misuse, and Dependence

Advise patients that MAS-ER Capsules are a federally controlled substance because it can be abused or lead to dependence. Additionally, emphasize that MAS-ER Capsules

should be stored in a safe place to prevent misuse and/or abuse. Evaluate patient history (including family history) of abuse or dependence on alcohol, prescription medicines, or illicit drugs [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9)].

Serious Cardiovascular Risks

Advise patients of serious cardiovascular risk (including sudden death, myocardial infarction, stroke, and hypertension) with MAS-ER Capsules. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during treatment should undergo a prompt cardiac evaluation [see Warnings and Precautions (5.2)].

Psychiatric Risks

Prior to initiating treatment with MAS-ER Capsules, adequately screen patients with comorbid depressive symptoms to determine if they are at risk for bipolar disorder. Such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and/or depression. Additionally, MAS-ER Capsule therapy at usual doses may cause treatment-emergent psychotic or manic symptoms in patients without prior history of psychotic symptoms or mania [see Warnings and Precautions (5.3)].

Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud's phenomenon]

Instruct patients beginning treatment with MAS-ER Capsules about the risk of peripheral vasculopathy, including Raynaud's Phenomenon, and in associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red. Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes. Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking MAS-ER Capsules. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients [see Warnings and *Precautions (5.6)*].

Serotonin Syndrome

Caution patients about the risk of serotonin syndrome with concomitant use of MAS-ER Capsules and other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort, and with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and also others such as linezolid [see Contraindications (4), Warnings and Precautions (5.7) and Drug Interactions (7.1)]. Advise patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.

Concomitant Medications

Advise patients to notify their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs because there is a potential for interactions *[see Drug Interactions (7.1)]*.

Growth

Monitor growth in children during treatment with MAS-ER Capsules, and patients who

are not growing or gaining weight as expected may need to have their treatment interrupted [see Warnings and Precautions (5.4)].

Pregnancy Registry

Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to MAS-ER Capsules during pregnancy [see Use in Specific Populations (8.1)].

Pregnancy

Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with MAS-ER Capsules. Advise patients of the potential fetal effects from the use of MAS-ER Capsules during pregnancy [see Use in Specific Populations (8.1)].

Lactation

Advise women not to breastfeed if they are taking MAS-ER Capsules [see Use in Specific Populations (8.2)].

Impairment in Ability to Operate Machinery or Vehicles

MAS-ER Capsules may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.

Distributed by **Prasco Laboratories**, Mason, OH 45040 USA Made in USA.

For more information call 1-866-525-0688.

ADDERALL[®] is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc. under license to Prasco Laboratories.

© 2020 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.

MEDICATION GUIDE

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate (DEX-troe-am-FET-uhmeen SACK-uh-rate, am-FET-uh-meen ass-PAR-tate mon-uh-HYED-rate, DEXtroe-am-FET-uh-meen SULL-fate, am-FET-uh-meen SULL-fate) Extended-Release Capsules MAS-ER Capsules CII

Read the Medication Guide that comes with MAS-ER Capsules before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about you or your child's treatment with MAS-ER Capsules.

What is the most important information I should know about MAS-ER Capsules?

MAS-ER Capsules are a stimulant medicine. The following have been reported with use of stimulant medicines.

1. Heart-related problems:

- sudden death in patients who have heart problems or heart defects
- stroke and heart attack in adults
- increased blood pressure and heart rate

Tell your doctor if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems.

Your doctor should check you or your child carefully for heart problems before starting MAS-ER Capsules.

Your doctor should check you or your child's blood pressure and heart rate regularly during treatment with MAS-ER Capsules.

Call your doctor right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking MAS-ER Capsules.

2. Mental (Psychiatric) problems:

All Patients

- new or worse behavior and thought problems
- new or worse bipolar illness
- new or worse aggressive behavior or hostility

Children and Teenagers

• new psychotic symptoms (such as hearing voices, believing things that are not true, are suspicious) or new manic symptoms

Tell your doctor about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.

Call your doctor right away if you or your child have any new or worsening mental symptoms or problems while taking MAS-ER Capsules, especially seeing or hearing things that are not real, believing things that are not real, or are suspicious.

<u>3. Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud's phenomenon]:</u>

- Fingers or toes may feel numb, cool, painful
- Fingers or toes may change from pale, to blue, to red

Tell your doctor if you have or your child has numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes.

Call your doctor right away if you have or your child has any unexplained wounds appearing on fingers or toes while taking MAS-ER Capsules.

What are MAS-ER Capsules?

MAS-ER Capsules are a once daily central nervous system stimulant prescription medicine. It is used for the treatment of Attention Deficit Hyperactivity **Disorder (ADHD).** MAS-ER Capsules may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD.

MAS-ER Capsules should be used as a part of a total treatment program for ADHD that may include counseling or other therapies.

MAS-ER Capsules are a federally controlled substance (CII) because it can be abused or lead to dependence. Keep MAS-ER Capsules in a safe place to prevent misuse and abuse. Selling or giving away MAS-ER Capsules may harm others, and is against the law.

Tell your doctor if you or your child have (or have a family history of) ever abused or been dependent on alcohol, prescription medicines or street drugs.

Who should not take MAS-ER Capsules?

MAS-ER Capsules should not be taken if you or your child:

- have heart disease or hardening of the arteries
- have moderate to severe high blood pressure
- have hyperthyroidism
- have an eye problem called glaucoma
- are very anxious, tense, or agitated
- have a history of drug abuse
- are taking or have taken within the past 14 days an anti-depression medicine called a monoamine oxidase inhibitor or MAOI.
- is sensitive to, allergic to, or had a reaction to other stimulant medicines

MAS-ER Capsules have not been studied in children less than 6 years old.

MAS-ER Capsules may not be right for you or your child. Before starting MAS-ER Capsules tell you or your child's doctor about all health conditions (or a family history of) including if you or your child:

- have heart problems, heart defects, or high blood pressure
- have mental problems including psychosis, mania, bipolar illness, or depression
- have tics or Tourette's syndrome
- have liver problems
- have kidney problems
- have end stage renal disease (ESRD)
- have thyroid problems
- have seizures or have had an abnormal brain wave test (EEG)
- have circulation problems in fingers and toes
- are pregnant or plan to become pregnant. It is not known if MAS-ER Capsules will harm your unborn baby.
 - There is a pregnancy registry for females who are exposed to MAS-ER Capsules during pregnancy. The purpose of the registry is to collect information about the health of females exposed to MAS-ER Capsules and their baby. If you or your child becomes pregnant during treatment with MAS-ER Capsules, talk to your healthcare provider about registering with the National Pregnancy Registry of Psychostimulants at 1-866-961-2388 or visit online at https://womensmentalhealth.org/clinical-and -researchprograms/pregnancyregistry/othermedications/.
 - are breastfeeding or plan to breastfeed. MAS-ER passes into breast milk. You or your child should not breastfeed during treatment with MAS-ER Capsules.

Can MAS-ER Capsules be taken with other medicines?

Tell your doctor about all of the medicines that you or your child takes including prescription and non-prescription medicines, vitamins, and herbal supplements. MAS-ER Capsules and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted while taking MAS-ER Capsules.

Your doctor will decide whether MAS-ER Capsules can be taken with other medicines. **Especially tell your doctor if you or your child takes:**

- anti-depression medicines including MAOIs
- anti-psychotic medicines
- lithium
- narcotic pain medicines
- seizure medicines
- blood thinner medicines
- blood pressure medicines
- stomach acid medicines
- cold or allergy medicines that contain decongestants

Know the medicines that you or your child takes. Keep a list of your medicines with you to show your doctor and pharmacist.

Do not start any new medicine while taking MAS-ER Capsules without talking to your doctor first.

How should MAS-ER Capsules be taken?

- Take MAS-ER Capsules exactly as prescribed. Your doctor may adjust the dose until it is right for you or your child.
- Take MAS-ER Capsules once a day in the morning when you first wake up. MAS-ER Capsules are an extended release capsule. It releases medicine into your body throughout the day.
- Swallow MAS-ER Capsules whole with water or other liquids. If you or your child cannot swallow the capsule, open it and sprinkle the medicine over a spoonful of applesauce. Swallow all of the applesauce and medicine mixture without chewing immediately. Follow with a drink of water or other liquid. **Never chew or crush the capsule or the medicine inside the capsule.**
- MAS-ER Capsules can be taken with or without food.
- From time to time, your doctor may stop MAS-ER Capsule treatment for a while to check ADHD symptoms.
- Your doctor may do regular checks of the heart and blood pressure while taking MAS-ER Capsules. Children should have their height and weight checked often while taking MAS-ER Capsules. MAS-ER Capsule treatment may be stopped if a problem is found during these check-ups.
- If you or your child takes too much MAS-ER Capsules or overdoses, call your doctor or poison control center right away, or get emergency treatment.

What are possible side effects of MAS-ER Capsules?

See "What is the most important information I should know about MAS-ER Capsules?" for information on reported heart and mental problems.

Other serious side effects include:

- slowing of growth (height and weight) in children
- seizures, mainly in patients with a history of seizures
- eyesight changes or blurred vision

Common side effects include:

- headache
- decreased appetite
- stomach ache
- nervousness
- trouble sleeping
- mood swings
- weight loss
- dizziness
- dry mouth
- fast heart beat

MAS-ER Capsules may affect you or your child's ability to drive or do other dangerous activities.

Talk to your doctor if you or your child has side effects that are bothersome or do not go away.

This is not a complete list of possible side effects. Ask your doctor or pharmacist for more information.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store MAS-ER Capsules?

- Store MAS-ER Capsules in a safe place at room temperature, 59 to 86° F (15 to 30° C).
- Keep MAS-ER Capsules and all medicines out of the reach of children.

General information about MAS-ER Capsules

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use MAS-ER Capsules for a condition for which it was not prescribed. Do not give MAS-ER Capsules to other people, even if they have the same condition. It may harm them and it is against the law.

This Medication Guide summarizes the most important information about MAS-ER Capsules. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about MAS-ER Capsules that was written for healthcare professionals.

For more information call 1-866-525-0688.

What are the ingredients in MAS-ER Capsules?

Active Ingredients: dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate

Inactive Ingredients: gelatin capsules, hydroxypropyl methylcellulose, methacrylic

acid copolymer, opadry beige, sugar spheres, talc, and triethyl citrate. Gelatin capsules contain edible inks, kosher gelatin, and titanium dioxide. The 5 mg, 10 mg, and 15 mg capsules also contain FD&C Blue #2. The 20 mg, 25 mg, and 30 mg capsules also contain red iron oxide and yellow iron oxide

Distributed by: **Prasco Laboratories** Mason, OH 45040 USA

© 2020 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.

Rev. 2/2022

This Medication Guide has been approved by the U.S. Food and Drug Administration.

PRINCIPAL DISPLAY PANEL - 5 mg Capsule Bottle Label

NDC 66993-594-02


CII

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product)

Extended-Release Capsules 5 mg

Pharmacist: Dispense with Attached Medication Guide.

100 Capsules Rx only



PRINCIPAL DISPLAY PANEL - 10 mg Capsule Bottle Label

NDC 66993-595-02


CII

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product)

Extended-Release Capsules 10 mg

Pharmacist: Dispense with Attached Medication Guide.

100 Capsules Rx only



PRINCIPAL DISPLAY PANEL - 15 mg Capsule Bottle Label

NDC 66993-596-02


CII

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product)

Extended-Release Capsules 15 mg

Pharmacist: Dispense with Attached Medication Guide.

100 Capsules Rx only



PRINCIPAL DISPLAY PANEL - 20 mg Capsule Bottle Label

NDC 66993-597-02


CII

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product)

Extended-Release Capsules 20 mg

Pharmacist: Dispense with Attached Medication Guide.

100 Capsules Rx only



PRINCIPAL DISPLAY PANEL - 25 mg Capsule Bottle Label

NDC 66993-598-02


CII

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product)

Extended-Release Capsules 25 mg

Pharmacist: Dispense with Attached Medication Guide.

100 Capsules Rx only



PRINCIPAL DISPLAY PANEL - 30 mg Capsule Bottle Label

NDC 66993-599-02


CII

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of A Single-Entity Amphetamine Product)

Extended-Release Capsules 30 mg

Pharmacist: Dispense with Attached Medication Guide.

100 Capsules Rx only



dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate capsule, extended release

Product Information					
Product mormation					
Product Type	HUMAN PRESCRIPTION DRUG	Item Co	ode (Source)	NDC	:66993-594
Route of Administration	ORAL	DEA Sc	hedule	CII	
Active Ingredient/Active	Moiety				
Ingred	ient Name		Basis of Strengt	h	Strength
DEXTROAMPHETAMINE SACCHA	. ,		DEXTROAMPHETAMINE SACCHARATE		1.25 mg
AMPHETAMINE ASPARTATE MON (AMPHETAMINE - UNII:CK833KGX7E)	OHYDRATE (UNII: O1ZPV6200)4)	AMPHETAMINE ASPARTATE MONOHYDRATE		1.25 mg
DEXTROAMPHETAMINE SULFATE (DEXTROAMPHETAMINE - UNII:TZ47U			DEXTROAMPHETAMINE SULFATE		1.25 mg
AMPHETAMINE SULFATE (UNII: 6	DPV8NK46S) (AMPHETAMINE -		AMPHETAMINE SULFATE		1.25 mg

Inactive Ingredients

		Ingredient Name			Strength
GELATIN, UNSPEC	IFIED (UNII: 2G86QN	1327L)			
HYPROMELLOSE,	UNSPECIFIED (UNII:	3NXW29V3WO)			
METHACRYLIC AC	D - METHYL METH	ACRYLATE COPOLYMER	(1:1)	(UNII: 74G4R6TH13)	
SUCROSE (UNII: C1	51H8M554)				
TALC (UNII: 7SEV7]	4R1U)				
TRIETHYL CITRATI	E (UNII: 8Z96QXD6UN	1)			
FD&C BLUE NO. 2	(UNII: L06K8R7DQK)				
TITANIUM DIOXIDI	E (UNII: 15FIX9V2JP)				
OPADRY YS-1-172	74A BEIGE (UNII: UF	P4CT4IW2C)			
Product Chara	acteristics				
Color	BLUE	Score		no score	
Shape	CAPSULE	Size		16mm	
Flavor		Imprint Code		M;Amphet;Salts;5;m	ng
Contains					
Packaging					
" the set of a dis	De ales a	- Description	Ν	Aarketing Start	Marketing End
# Item Code	Раскад	e Description		Date	Date
		ype 0: Not a Combination	04/	02/2009	
- 02	Product				
Marketing	Information				
Marketing Category	Application	Number or Monogra Citation	ph	Marketing Start Date	Marketing End Date
					Dutt
GENERIC	NDA021303			04/02/2009	

dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate capsule, extended release

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Co	ode (Source)	NDC:66993-595
Route of Administration	ORAL	DEA Sc	hedule	CII
Active Ingredient/Active	Moiety			
	Moiety lient Name		Basis of Strengt	th Strength
-	lient Name RATE (UNII: G83415V073)		Basis of Strengt DEXTROAMPHETAMINE SACCHARATE	th Strength 2.5 mg

(AMPHETAMINE - UNII:CK833KGX7E)	MONOHYDRATE	2.5 mg
DEXTROAMPHETAMINE SULFATE (UNII: JJ7680327N) (DEXTROAMPHETAMINE - UNII:TZ47U051FI)	DEXTROAMPHETAMINE SULFATE	2.5 mg
AMPHETAMINE SULFATE (UNII: 6DPV8NK46S) (AMPHETAMINE - UNII:CK833KGX7E)	AMPHETAMINE SULFATE	2.5 mg

Inactive Ingre	aichts				
		Ingredient Name			Strengt
GELATIN, UNSPEC	IFIED (UNII: 2G86Q)	-			
HYPROMELLOSE,					
-		ACRYLATE COPOLYMER (1	: 1) (l	JNII: 74G4R6TH13)	
SUCROSE (UNII: C1	51H8M554)				
TALC (UNII: 7SEV7]	4R1U)				
TRIETHYL CITRATI	: (UNII: 8Z96QXD6U	M)			
FD&C BLUE NO. 2	(UNII: L06K8R7DQK)				
TITANIUM DIOXIDI	(UNII: 15FIX9V2JP)				
OPADRY YS-1-172	74A BEIGE (UNII: U	P4CT4IW2C)			
Product Chara	acteristics				
Color	BLUE	Score		no score	
Shape	CAPSULE	Size		16mm	
Flavor		Imprint Code		M;Amphet;Salts;10;m	ng
Contains					
Packaging					
# Item Code	Packag	ge Description	М	arketing Start Date	Marketing Enc
		•			Dutt
1 NDC:66993-595- 02	100 in 1 BOTTLE; T Product	ype 0: Not a Combination	04/0	2/2009	Dutt
1 NDC:66993-595-			04/0	2/2009	Dute
1 NDC:66993-595- 02	Product	ype 0: Not a Combination	04/0	2/2009	Dute
1 NDC:66993-595-	Product	ype 0: Not a Combination			
1 NDC:66993-595- 02	Product	ype 0: Not a Combination		2/2009 Marketing Start Date	Marketing End Date

dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate capsule, extended release

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:66993-596

DEA Schedule

CII

		Ingredient I	Name	Ba	sis of Stre	ength	Strengt
		MINE SACCHARATE NE - UNII:TZ47U051FI		DEXTRO SACCH	DAMPHETAMIN ARATE	NE	3.75 mg
	IPHETAMINE AS 1PHETAMINE - UNI		ORATE (UNII: 01ZPV62004)		TAMINE ASPAN IYDRATE	RTATE	3.75 mg
	(TROAMPHETAMINE SULFATE (UNII: JJ768O327N) (TROAMPHETAMINE - UNII:TZ47U051FI)			DEXTRO SULFAT	DAMPHETAMIN E	NE	3.75 mg
	IPHETAMINE SU II:CK833KGX7E)	ETAMINE SULFATE (UNII: 6DPV8NK46S) (AMPHETAMINE - K833KGX7E)			TAMINE SULFA	ATE	3.75 mg
In	active Ingre	dients					
			Ingredient Name				Strength
GE	LATIN, UNSPEC	IFIED (UNII: 2G86QN3	327L)				
ΗY	PROMELLOSE,	UNSPECIFIED (UNII: 3	3NXW29V3WO)				
ME	THACRYLIC ACI	D - METHYL METHA	CRYLATE COPOLYMER (1	1) (UNII: 74G4	4R6TH13)		
รบ	CROSE (UNII: C1	51H8M554)					
ТΑ	LC (UNII: 7SEV7J4	4R1U)					
TR	IETHYL CITRATE	E (UNII: 8Z96QXD6UM					
EP							
- 0	AC BLUE NO. 2	(UNII: L06K8R7DQK)					
		(UNII: 15FIX9V2JP)					
TIT	ANIUM DIOXIDE		4CT4IW2C)				
TIT	ANIUM DIOXIDE	E (UNII: 15FIX9V2JP)	4CT4IW2C)				
TIT	ANIUM DIOXIDE	E (UNII: 15FIX9V2JP)	4CT4IW2C)				
ΟΡ	ANIUM DIOXIDE	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4	4CT4IW2C)				
TIT OP Pr	ANIUM DIOXIDE ADRY YS-1-172	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4	4CT4IW2C) Score	no sco	ore		
TIT OP Pr Co	ANIUM DIOXIDE ADRY YS-1-172 Oduct Chara Ior	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 ACTERISTICS BLUE, WHITE	Score				
TIT OP Pr Co Sh	ANIUM DIOXIDE ADRY YS-1-172 Oduct Chara Ior ape	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 Acteristics	Score Size	18mm	l	·ma	
TIT OP Pr Co Sh Fla	ANIUM DIOXIDE ADRY YS-1-172 Oduct Chara lor ape avor	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 ACTERISTICS BLUE, WHITE	Score	18mm		;mg	
TIT OP Pr Co Sh Fla	ANIUM DIOXIDE ADRY YS-1-172 Oduct Chara Ior ape	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 ACTERISTICS BLUE, WHITE	Score Size	18mm	l	;mg	
TIT OP Pr Co Sh Fla	ANIUM DIOXIDE ADRY YS-1-172 Oduct Chara lor ape avor	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 ACTERISTICS BLUE, WHITE	Score Size	18mm	l	;mg	
TIT OP Co Sh Fla Co	ANIUM DIOXIDE ADRY YS-1-172 oduct Chara lor ape avor ntains	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 ACTERISTICS BLUE, WHITE	Score Size	18mm	l	;mg	
TIT OP Co Sh Fla Co	ANIUM DIOXIDE ADRY YS-1-172 Oduct Chara lor ape avor	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 ACTERISTICS BLUE, WHITE	Score Size	18mm M;Amp	bhet;Salts;15;		
TIT OP Co Sh Fla Co	ANIUM DIOXIDE ADRY YS-1-172 oduct Chara lor ape avor ntains	E (UNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 ACTERISTICS BLUE, WHITE CAPSULE	Score Size	18mm	ohet;Salts;15; g Start	Marke	ting End
Pr Co Sh Fla Co	roduct Chara lor ape avor ntains ackaging Item Code	Cteristics BLUE, WHITE CAPSULE Package	Score Size Imprint Code	18mm M;Amp Marketin Dat	ohet;Salts;15; g Start	Marke	-
Pr Co Sh Fla Co	roduct Chara lor ape avor ntains ackaging Item Code	Cteristics BLUE, WHITE CAPSULE Package	Score Size Imprint Code	18mm M;Amp Marketin	ohet;Salts;15; g Start	Marke	-
Pr Co Sh Fla Co	ANIUM DIOXIDE ADRY YS-1-172 roduct Chara lor ape avor ntains ackaging item Code NDC:66993-596-	Cteristics CAPSULE Package 100 in 1 BOTTLE; Ty	Score Size Imprint Code	18mm M;Amp Marketin Dat	ohet;Salts;15; g Start	Marke	-
Pr Co Sh Fla Co	ANIUM DIOXIDE ADRY YS-1-172 roduct Chara lor ape avor ntains ackaging item Code NDC:66993-596-	Cteristics CAPSULE Package 100 in 1 BOTTLE; Ty	Score Size Imprint Code	18mm M;Amp Marketin Dat	ohet;Salts;15; g Start	Marke	_
Pr Co Sh Fla Co	ANIUM DIOXIDE ADRY YS-1-172 roduct Chara lor ape avor ntains ackaging item Code	CUNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 CAPSULE CAPSULE 100 in 1 BOTTLE; Typ Product	Score Size Imprint Code	18mm M;Amp Marketin Dat	ohet;Salts;15; g Start	Marke	_
Pr Co Sh Fla Co	ANIUM DIOXIDE ADRY YS-1-172 roduct Chara lor ape avor ntains ackaging item Code NDC:66993-596- 02 arketing	CUNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 CAPSULE CAPSULE 100 in 1 BOTTLE; Typ Product	Score Size Imprint Code Description pe 0: Not a Combination	18mm M;Amp Marketin Dat 04/02/2009 Market	g Start e	Marke D Marke	Pate eting End
Pr Co Sh Fla Co Pa #	ADRY YS-1-172 Coduct Chara lor ape avor intains ackaging item Code NDC:66993-596- 02 arketing	CUNII: 15FIX9V2JP) 74A BEIGE (UNII: UP4 CAPSULE CAPSULE 100 in 1 BOTTLE; Typ Product	Score Size Imprint Code	18mm M;Amp Marketin Dat 04/02/2009 Market	g Start e Sing Start ate	Marke D Marke	oate

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE,

DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE

dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate capsule, extended release

Product Infor	mation					
Product Type		HUMAN PRESCRIPTION DRUG	Item Co	de (Source)	NDC	:66993-59
Route of Admini	stration	ORAL	DEA Sch	DEA Schedule		
Active Ingredi	ent/Active I	Moiety				
	Ingredi	ent Name		Basis of Str	ength	Strengt
DEXTROAMPHETAMINE SACCHARATE (UNII: G83415V073)DEXTROAMPHETAMINE(DEXTROAMPHETAMINE - UNII:TZ47U051FI)SACCHARATE						5 mg
AMPHETAMINE ASPARTATE MONOHYDRATE (UNII: 01ZPV62004)AMPHETAMINE ASPARTATE MONOHYDRATE(AMPHETAMINE - UNII:CK833KGX7E)MONOHYDRATE						5 mg
DEXTROAMPHETAMINE SULFATE (UNII: JJ7680327N)DEXTROAMPHETAMINE(DEXTROAMPHETAMINE - UNII:TZ47U051FI)SULFATE						5 mg
AMPHETAMINE SU UNII:CK833KGX7E)	LFATE (UNII: 6D	PV8NK46S) (AMPHETAMINE -		AMPHETAMINE SULF	FATE	5 mg
Inactive Ingre	dients					
		Ingredient Name				Strengt
GELATIN, UNSPEC						
		UNII: 3NXW29V3WO)				
		ETHACRYLATE COPOLYMER	r (1:1) (UN	ll: 74G4R6TH13)		
SUCROSE (UNII: C1	·					
TALC (UNII: 7SEV7J4						
OPADRY YS-1-172	74A BEIGE (UN	II: UP4C14IW2C)				
Product Chara	cteristics					
Color	ORANGE	Score	nc	o score		
Shape	CAPSULE	Size	18	.8mm		
Flavor	Imprint Code M;Amphet;Salts;20;mg			ng		
Contains					5	
Packaging						
# Item Code	Pac	kage Description	Mar	keting Start Date		ing End ate
1 NDC:66993-597- 02	100 in 1 BOTTL Product	E; Type 0: Not a Combination	04/02/2	2009		

Marketing Category	Applica	ation Number or Monogr Citation	aph N	Marketing Start Date		eting End Date
NDA AUTHORIZ ED GENERIC	NDA02130	3	04,	/02/2009		
		INE SACCHARATE INE SULFATE, AN	-			-
		ate, amphetamine aspart				
•		lfate capsule, extended r		,		
Product Inform	nation					
Product Type		HUMAN PRESCRIPTION DRUG	Item Co	ode (Source)	NE	C:66993-598
Route of Administ	tration	ORAL	DEA Scl	hedule	CI	
Active Ingredie	nt/Active	Moiety				
		ient Name		Basis of Stre	ngth	Strengt
DEXTROAMPHETAM (DEXTROAMPHETAMIN		RATE (UNII: G83415V073) U051FI)		DEXTROAMPHETAMINE SACCHARATE		6.25 mg
AMPHETAMINE ASPA (AMPHETAMINE - UNII:		NOHYDRATE (UNII: 01ZPV620	04)	AMPHETAMINE ASPAR MONOHYDRATE	RTATE	6.25 mg
DEXTROAMPHETAM (DEXTROAMPHETAMIN				DEXTROAMPHETAMIN SULFATE	E	6.25 mg
AMPHETAMINE SULI UNII:CK833KGX7E)	F ATE (UNII: 6	DPV8NK46S) (AMPHETAMINE -		AMPHETAMINE SULFA	TE	6.25 mg
Inactive Ingred	ients					
		Ingredient Name				Strength
GELATIN, UNSPECIF						
HYPROMELLOSE, UI		(UNII: 3NXW29V3WO) IETHACRYLATE COPOLYME	R (1:1) (UN	JUI: 74G486TH13)		
SUCROSE (UNII: C15:			(112) (0)			
TALC (UNII: 7SEV7J4R	.1U)					
TRIETHYL CITRATE	(UNII: 8Z96Q>	(D6UM)				
FERRIC OXIDE RED	(UNII: 1K09F3)	G675)				
FERRIC OXIDE YELL						
TITANIUM DIOXIDE		-				
OPADRY YS-1-1727	4A BEIGE (UI	NII: UP4CT4IW2C)				
Product Charac	teristics					
Product Charac	C teristics DRANGE, WHIT	TE Score		no score		
Color		E Score Size		no score 21mm		

Contains

Packaging								
#	ltem Code	Package Description	Package Description Marketing Start Marketing Date Date Date Date Date Date Date Date					
-	NDC:66993-598- 02	100 in 1 BOTTLE; Type 0: Not a Combination Product	04/02/2009					
м	arkoting	nformation						
M	arketing l	nformation						
M	arketing Marketing Category	nformation Application Number or Monograpl Citation	h Marketing Star Date	t Marketing End Date				
NDA	Marketing	Application Number or Monograp	-	-				
ND	Marketing Category A AUTHORIZED	Application Number or Monograpl Citation	Date	-				

dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate capsule, extended release

Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	ltem C	Code (Source) NDC:669		
Route of Administration	ORAL	DEA Sc	hedule	CII	
Active Ingredient/Active	Moiety				
Ingredient Name Basis of Strength					
DEXTROAMPHETAMINE SACCHA (DEXTROAMPHETAMINE - UNII:TZ47			DEXTROAMPHETAMINE SACCHARATE	7.5 mg	
AMPHETAMINE ASPARTATE MONOHYDRATE (UNII: 01Z PV62004)AMPHETAMINE ASPARTATE(AMPHETAMINE - UNII:CK833KGX7E)MONOHYDRATE					
DEXTROAMPHETAMINE SULFATE (UNII: JJ7680327N)DEXTROAMPHETAMINE(DEXTROAMPHETAMINE - UNII:TZ47U051FI)SULFATE					
AMPHETAMINE SULFATE (UNII: 6DPV8NK46S) (AMPHETAMINE - UNII: CK833KGX7E) AMPHETAMINE SULFATE				7.5 mg	
Inactive Ingredients					
	Ingredient Name			Strength	
GELATIN, UNSPECIFIED (UNII: 2G	86QN327L)				
HYPROMELLOSE, UNSPECIFIED	(UNII: 3NXW29V3WO)				
METHACRYLIC ACID - METHYL M	IETHACRYLATE COPOLYMER	t (1:1) (U	NII: 74G4R6TH13)		
SUCROSE (UNII: C151H8M554)					
TALC (UNII: 7SEV7J4R1U)					
TRIETHYL CITRATE (UNII: 8Z96Q>	(D6UM)				
FERRIC OXIDE RED (UNII: 1K09F30					
FERRIC OXIDE YELLOW (UNII: EX	43802MRT)				
TITANIUM DIOXIDE (UNII: 15FIX9V	(2JP)				
OPADRY YS-1-17274A BEIGE (UI	NII: UP4CT4IW2C)				

P	roduct Chara	acteristics					
Co	olor	BROWN, ORANGE	Score		no score		
Sh	nape	CAPSULE	Size		21mm		
Fla	avor		Imprint Code		M;Amphet;Salts	;30;mg	
Co	ontains						
Pa	ackaging						
#	ltem Code	Package Desci	ription		eting Start Date	Marketing End Date	
1	NDC:66993-599- 02	100 in 1 BOTTLE; Type 0: Not Product	a Combination	04/02/200	09		
Μ	Marketing Information						
	Marketing Category	Application Numbe Citati		Maı	rketing Start Date	Marketing End Date	
	DA AUTHORIZED	NDA021303		04/02,	/2009		

Labeler - Prasco Laboratories (065969375)

Establishment				
Name	Address	ID/FEI	Business Operations	
Cambrex Charles City, Inc		782974257	API MANUFACTURE(66993-594, 66993-595, 66993-596, 66993-597, 66993- 598, 66993-599)	

Establishment

Name	Address	ID/FEI	Business Operations
Patheon Manufacturing Services LLC		079415560	ANALYSIS(66993-594, 66993-595, 66993-596, 66993-597, 66993-598, 66993-599) , LABEL(66993-594, 66993-595, 66993-596, 66993-597, 66993-598, 66993-599) , MANUFACTURE(66993-594, 66993-595, 66993-596, 66993-597, 66993-598, 66993-599) , PACK(66993-594, 66993-595, 66993-596, 66993-597, 66993-598, 66993-599)

Establishment

Name	Address	ID/FEI	Business Operations
Unither Manufacturing LLC		079176615	ANALYSIS(66993-595, 66993-596, 66993-597, 66993-598, 66993-599) , MANUFACTURE(66993-595, 66993-596, 66993-597, 66993-598, 66993-599)

Establishment					
Name	Address	ID/FEI	Business Operations		
Sharp Packaging Services, LLC		143696495	LABEL(66993-594, 66993-595, 66993-596, 66993-597, 66993-598, 66993-599) , PACK(66993-594, 66993-595, 66993-596, 66993-597, 66993-598, 66993-599)		